US Patent

US11844756 — Compositions and methods for treating anemia

Method of Use · Assigned to Akebia Therapeutics Inc · Expires 2036-03-31 · 10y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects specific doses and dosing regimens for using a HIF prolyl hydroxylase inhibitor, such as vadadustat, to treat or prevent anemia.

USPTO Abstract

Provided herein are specific doses of, and dosing regimens for, using a HIF prolyl hydroxylase inhibitor in treating or preventing anemia, such as anemia secondary to or associated with chronic kidney disease, anemia secondary to or associated with non-dialysis dependent chronic kidney disease anemia associated with or resulting from chemotherapy, or anemia associated with AIDS.

Drugs covered by this patent

vadadustat (VADADUSTAT)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3876`	—	vadadustat
`U-3876`	—	vadadustat
`U-3876`	—	vadadustat

Patent Metadata

Patent number: US11844756
Jurisdiction: US
Classification: Method of Use
Expires: 2036-03-31
Drug substance claim: No
Drug product claim: No
Assignee: Akebia Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.